Nienke E. Haverkate

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Journal: Blood advances
Published: May 23, 2025

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Journal: Blood advances
Published: May 23, 2025

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Journal: Blood advances
Published: May 23, 2025

T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines.

T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines.

Journal: Haematologica
Published: December 06, 2024

Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer.

Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer.

Journal: Cytotherapy
Published: July 23, 2023

Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo.

Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo.

Journal: Cytotherapy
Published: July 17, 2023

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.

Journal: EClinicalMedicine
Published: March 01, 2023

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.

Journal: JAMA oncology
Published: August 11, 2022

Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study.

Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study.

Journal: Transplantation and cellular therapy
Published: July 12, 2022

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.

Journal: Blood advances
Published: December 27, 2021

Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.

Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.

Journal: Science translational medicine
Published: October 18, 2019

Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease.

Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease.

Journal: Blood advances
Published: March 18, 2019
Showing 1-12 of 12

Last Updated: 09/26/2026